Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 2/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | SYK | P43405 | 12/20 | 0.50 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.48 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4920899 | 0.86 | ADORA3 (0.53) | SYKIGF1RADORA3ADORA2AADORA1 | |
| SCHEMBL21601504 | 0.81 | ADORA3 (0.69) | SYKADORA3ADORA2AADORA1 | |
| SCHEMBL21601563 | 0.81 | ADORA3 (0.69) | SYKADORA3ADORA2AADORA1 | |
| SCHEMBL21601510 | 0.81 | ADORA3 (0.69) | SYKADORA3ADORA2AADORA1 | |
| SCHEMBL31061104 | 0.81 | ADORA3 (0.69) | SYKADORA3ADORA2AADORA1 | |
| SCHEMBL10171951 | 0.81 | IRAK4 (0.63) | — | |
| SCHEMBL4909020 | 0.80 | ADORA3 (0.48) | ADORA3ADORA2AADORA1 | |
| SCHEMBL7104515 | 0.80 | ADORA3 (0.64) | SYKADORA3ADORA2AADORA1 | |
| SCHEMBL4649801 | 0.79 | NEK2 (0.55) | NEK2CDK2SYKCDK19ALK | |
| SCHEMBL4916898 | 0.78 | ADORA3 (0.45) | SYKADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | GRK4, JAK2, ALK | NEK2 609/4885CDK2 252/4885SYK 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.